Published : Jul-2017
No. of Pages : 47
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Acute Myeloid Leukemia: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.3 Global and Historical Trends 10
3.3.1 Incidence 10
3.3.2 Relative Survival 12
3.3.3 Subtypes 13
3.4 Forecast Methodology 13
3.4.1 Sources 15
3.4.2 Forecast Assumptions and Methods - Population 19
3.4.3 Forecast Assumptions and Methods - Incidence 19
3.4.4 Forecast Assumptions and Methods - Relative Survival 23
3.4.5 Forecast Assumptions and Methods - Subtypes of AML 24
3.4.6 Forecast Assumptions and Methods - Mutations and Biomarkers 25
3.4.7 Forecast Assumptions and Methods - Risk Groups 27
3.5 Epidemiological Forecast for Acute Myeloid Leukemia (2016-2026) 29
3.5.1 Adjusted Diagnosed Incident Cases of AML 29
3.5.2 Age-Specific Diagnosed Incident Cases of AML 30
3.5.3 Diagnosed Incident Cases of APL 31
3.5.4 Diagnosed Incident Cases of Secondary AML 32
3.5.5 Diagnosed Incident Cases of AML by Mutations and Biomarkers 33
3.5.6 Diagnosed Incident Cases of AML by Risk Groups 34
3.5.7 Five-Year Diagnosed Prevalent Cases of AML 35
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
3.6.2 Limitations of Analysis 37
3.6.3 Strengths of Analysis 39
4 Appendix 40
4.1 Bibliography 40
4.2 About the Authors 45
4.2.1 Epidemiologist 45
4.2.2 Reviewers 45
4.2.3 Global Director of Therapy Analysis and Epidemiology 45
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 46
4.3 About GlobalData 47
4.4 Contact Us 47
4.5 Disclaimer 47
1.1 List of Tables
Table 1: Risk Factors for AML in Adults 10
Table 2: AML Coding System by Country 11
Table 3: Five-Year Relative Survival of AML by Age, 2016 12
Table 4: Risk Group Classification Guidelines 28
Table 5: 7MM, Adjusted Diagnosed Incident Cases of AML, Ages =18 Years, Both Sexes, Select Years 2016-2026 30
Table 6: 7MM, Age-Specific Adjusted Diagnosed Incident Cases of AML, Both Sexes, 2016 31
Table 7: 7MM, Mutations and Biomarkers in Diagnosed Incident Cases of AML, Ages =18 Years, Both Sexes, 2016 34
Table 8: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Ages =18 Years, Both Sexes, Select Years 2016-2026 36
1.2 List of Figures
Figure 1: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages =18 Years, 2016 and 2026 5
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages =18 Years, 2016 and 2026 6
Figure 3: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages =18 Years, 2016 12
Figure 4: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of AML 15
Figure 5: 7MM Sources Used, Relative Survival of AML 16
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of APL 17
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of Secondary AML 18
Figure 8: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages =18 Years, 2016 32
Figure 9: 7MM, Diagnosed Incident Cases of Secondary AML, Both Sexes, Ages =18 Years, 2016 33
Figure 10: 7MM, Diagnosed Incident Cases of AML by Risk Group, Both Sexes, Ages =18 Years, 2016 35
Figure 11: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, 2016 36
